ClinicalTrials.gg
CompletedNCT03394807LaGRAUpdated Jan 9, 2018

LaGRA Trial in Laparoscopic Cholecystectomy

A Phase 4 interventional study of Levobupivacaine and Placebo in Regional Anesthesia Morbidity, Gallbladder Stone and Pain, sponsored by Health Service Executive, Ireland. Completed. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2018-01-09.

Sponsored by Health Service Executive, Ireland · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 2 months after the study started (first participant enrolled Oct 2016, registered Dec 2017).
Phase
Phase 4
Study type
Interventional
Enrollment
76
Allocation
Randomized
Ages
16 Years and older
Sex
All
01

Study summary

This study investigated the effectiveness of a surgeon administered, laparoscopic guided, regional anaesthesia technique.

Read the detailed description

A prospective, double blind, randomised controlled trial was performed. Consenting patients undergoing laparoscopic cholecystectomy were randomised, by envelope, to a laparoscopic guided 2-point blockade (subcostal transversus abdominis plane and rectus sheath) using either Chirocaine® 2.5mg/ml (LaGRA) or 0.9% Saline (Placebo) after specimen extraction.

Primary endpoints were post-operative pain in the first 6 hours. Secondary endpoints were analgesic/anti-emetic usage and day case and re-admission rates. Data was analysed using GraphPad Prism (V7).

02

Conditions studied

  • Regional Anesthesia Morbidity
  • Gallbladder Stone
  • Pain
03

In context

Cholecystolithiasis

88 studies on the registry are indexed under Cholecystolithiasis; 17 are open to participants now.

This study's enrollment of 76 is below the median of 100 across 59 interventional studies indexed under Cholecystolithiasis.

Browse Cholecystolithiasis studies →

Lead sponsor

Health Service Executive, Ireland is the lead sponsor of 6 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients undergoing laparoscopic cholecystectomy
  • , II or III

Exclusion criteria

Exclusion Criteria:

  • Patients that don't consent to be included
  • Allergy to levobupivacaine
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
76 participants (actual)

Study arms

  • Experimental
    LaGRA

    regional anaesthesia of the right upper quadrant by injection of levobupivacaine 0.25% to the transversus abdominis plane and the rectus sheath under laparoscopic guidance immediately following specimen removal

    Drug: Levobupivacaine

  • Placebo comparator
    Placebo

    Sham regional anaesthesia of the right upper quadrant by injection of Saline 0.9% to the transversus abdominis plane and the rectus sheath under laparoscopic guidance immediately following specimen removal

    Drug: Placebo

Interventions

  • Levobupivacaine injection to Transversus abdominis plane and rectus sheath

    Also known as: Chirocaine

  • DrugPlacebo

    Saline injection to Transversus abdominis plane and rectus sheath

    Also known as: Saline

06

What researchers measure

Primary outcomes

  1. Post operative pain score

    Visual analogue pain scores ranging from 0 to 10

    Time frame: 6 hours post operatively

Secondary outcomes

  1. Opioid use

    Amount (mg) of opioid medication administered

    Time frame: Perioperative period including first 6 hours post operatively

  2. Analgesic use

    Type and dose of all non opioid analgesic medications prescribed

    Time frame: Perioperative period including first 6 hours post operatively

  3. Readmission rate

    Patient readmitted to hospital for any reason

    Time frame: 30 days post operative

  4. Daycase rates

    Patient that was planned for daycase but admitted overnight

    Time frame: Day of surgery

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2016 to primary completion in Jul 2017, 9 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 15, 2017
First posted
Jan 9, 2018
StartActual
Oct 1, 2016
Primary completionActual
Jul 30, 2017
CompletionActual
Aug 30, 2017
Last update
Jan 9, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 9, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03394807
Lead sponsor
Health Service Executive, Ireland
Responsible party
Des Toomey (Consultant Surgeon, Health Service Executive, Ireland) — Principal investigator
First posted
Jan 9, 2018
Start date
Oct 1, 2016
Primary completion
Jul 30, 2017
Completion
Aug 30, 2017
Last update
Jan 9, 2018

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Levobupivacaine

Start the discussion